Ji Rui

Dr. Ji Rui


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2023 in Digestion
Verified
Journal Article
Open access
PDF file
WZWen-Lin Zhang
Wen-Lin Zhang
BLBo-Shen Lin
Bo-Shen Lin
YLYue-Yue Li
Yue-Yue Li
YDYu-Ming Ding
Yu-Ming Ding
ZHZhong-Xue Han
Zhong-Xue Han
JRJi Rui
Ji Rui
Introduction: Vonoprazan, a novel potassium-competitive acid blocker, has a strong acid suppression effect and potent efficacy in acid-associated diseases, including Helicobacter pylori eradication. We performed a systematic review and meta-analysis to investigate the efficacy and safety of vonoprazan/amoxicillin dual therapy for H. pylori eradication. Methods: We conducted a systematic literature search through PubMed, Web of Science, EMBASE, and the Cochrane Library up to June 2022, to identify randomized controlled trials and cohort studies comparing vonoprazan/amoxicillin dual therapy and triple therapies for H. pylori eradication. Primary outcomes were cure rates and relative efficacy. Secondary outcomes included adverse events, dropout rate, and subgroup analysis. Results: Five studies with 1,852 patients were included in the analysis. The cure rates of vonoprazan/amoxicillin dual therapy were 85.6% with 95% confidence interval (CI) of 79.7–91.5% and 88.5% (95% CI: 83.2–93.8%) in the intention-to-treat and per-protocol analyses. The efficacy of vonoprazan/amoxicillin dual therapy was not inferior to that of triple therapy with pooled risk ratio (RR) of 1.03 (95% CI: 0.97–1.10) and 1.02 (95% CI: 0.98–1.08) in intention-to-treat and per-protocol analyses; while it was significantly superior to the omeprazole or lansoprazole-based triple therapy (RR = 1.15, 95% CI: 1.05–1.25, p = 0.001). For clarithromycin-resistant strains, vonoprazan/amoxicillin dual therapy showed superiority to vonoprazan-based triple therapy (86.7% vs. 71.4%, RR = 1.20, 95% CI: 1.03–1.39, p = 0.02); however, vonoprazan/amoxicillin dual therapy was significant inferior to vonoprazan-based triple therapy for clarithromycin-sensitive strains (83.0% vs. 92.8%, RR = 0.90, 95% CI: 0.85–0.95, p = 0.0002). The adverse effects of vonoprazan/amoxicillin dual therapy were lower than those of triple therapy (21.2% vs. 26.5%, RR = 0.86, 95% CI: 0.73–1.01, p = 0.06), especially the incidence of diarrhea (p = 0.01). Conclusions: The efficacy of vonoprazan/amoxicillin dual therapy is noninferior to vonoprazan-based triple therapy but superior to the omeprazole or lansoprazole-based triple therapy and has less side effects. Patients with clarithromycin-resistant strains are particularly expected to benefit from vonoprazan/amoxicillin dual therapy.

13 November 2022 in Digestive Endoscopy
Verified
Journal Article
Closed access
XYXiaoxiao Yang
Xiaoxiao Yang
SFShichen Fu
Shichen Fu
LLLixiang Li
Lixiang Li
JYJialin Yang
Jialin Yang
JRJi Rui
Ji Rui
XZXiuli Zuo
Xiuli Zuo

5 March 2024 in Helicobacter
Verified
Journal Article
Closed access
SWShao‐Tong Wang
Shao‐Tong Wang
HYHua‐Wei Yang
Hua‐Wei Yang
WZWen‐Lin Zhang
Wen‐Lin Zhang
ZLZhen Li
Zhen Li
JRJi Rui
Ji Rui

10 October 2022 in Endoscopy
Verified
Journal Article
Open access
PDF file
WZWen-Lin Zhang
Wen-Lin Zhang
JRJi Rui
Ji Rui
Calculus in a cystic duct remnant is one of the causes of postcholecystectomy syndrome. Surgical extraction of the stone with excision of the cystic duct can be carried out, but the adhesions caused by the prior operation make the reoperation more challenging [1]. Endoscopic retrograde cholangiopancreatography (ERCP) has been used to extract the stone in combination with lithotripsy [2] [3] [4], but is confined to only a small subset of patients. We present a novel peroral choledochoscope (Eye-Max CDS11001; Micro-Tech, China) with a 1.8-mm working channel to introduce therapeutic equipment ([Fig. 1]). A 69-year-old man experienced right upper quadrant abdominal pain on the 5th day after laparoscopic cholecystectomy. ERCP showed an 8 mm × 8 mm filling defect in the cystic duct stump ([Fig. 2]), suggesting a retained stone. Because of the limited stump length, attempts to grab the stone by retrieval basket and balloon both failed. A peroral choledochoscope was used for further exploration ([Video 1]). When the digital catheter reached the cystic duct, a dark brown stone was seen in the cystic duct stump ([Fig. 3]). A four-wire retrieval basket (CEB01010, open diameter 15 mm; Micro-Tech (Nanjing) Co., P. R. China) was then inserted into the bile duct through the working channel of the peroral choledochoscope. Under direct visualization, the stone was successfully grasped with the basket ([Fig. 4]). The stone was cautiously pulled into the common bile duct and then the duodenum. Repeat cholangiography showed no stones retained. The patient was discharged without further event after 5 days. Video 1 Removal of a stone in the cystic duct stump using a retrieval basket under direct visualization by a novel peroral choledochoscope. We present a new endoscopic technique for minimally invasive extraction of a stone or stones in a cystic duct remnant, thus avoiding a second surgical operation. More cases and longer follow-up are needed to validate the advantage of this technique. Endoscopy_UCTN_Code_TTT_1AR_2AH Article published online: 10 October 2022 © 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

2 December 2025 in Endoscopy
Verified
Journal Article
Closed access
PDF file
RZRuixin Zhang
Ruixin Zhang
JRJi Rui
Ji Rui
MLMaosheng Li
Maosheng Li
XYXiaoxiao Yang
Xiaoxiao Yang
JLJiaoyang Lu
Jiaoyang Lu
XZXiuli Zuo
Xiuli Zuo
Several animal studies have demonstrated the safety and efficacy of a flexible auxiliary single-arm transluminal endoscopic robot in assisting gastric endoscopic submucosal dissection (ESD). This study aimed to assess its performance for the first time in a real clinical setting. We conducted this prospective, single-blind, pilot randomized controlled trial at a tertiary teaching hospital. Patients with gastric high grade intraepithelial neoplasia or intramucosal carcinoma were randomized to either robot-assisted or conventional ESD. The primary outcome was procedure time. Secondary outcomes included R0 and en bloc resection rates, dissection time, and procedure-related complications. 48 patients underwent successful procedures without perforation. Despite no significant difference in procedure time between robot-assisted and conventional ESD (58.21 vs. 39.21 minutes; P = 0.08), a learning curve effect was observed, with shorter procedure times in the last 12 cases with robot assistance compared with the last 12 conventional ESDs (56.82 vs. 63.10 minutes; P = 0.71). Muscular injuries were significantly reduced with robot assistance (1.50 vs. 9.00; P < 0.001). No significant difference was found in R0 (95.8% vs. 91.7%; P > 0.99) and en bloc (100% vs. 95.8%; P > 0.99) resection rates between robot-assisted and conventional ESD, respectively. This preliminary evidence supports the feasibility of robot-assisted gastric ESD.

9 January 2024 in Endoscopy
Verified
Journal Article
Open access
PDF file
CCCan Cui
Can Cui
XLXuefeng Lu
Xuefeng Lu
XZXiu-Li Zuo
Xiu-Li Zuo
JRJi Rui
Ji Rui
Endoscopic submucosal dissection (ESD) is the standard technique for resection of gastric superficial tumors. However, in difficult locations of the stomach, a vertical approach toward the muscular layer is always unavoidable and results in a higher risk of damage [1]. To help address these issues, we designed a flexible auxiliary single-arm transluminal endoscopic robot (FASTER). The operator can utilize its external control system to precisely manipulate the grasping forceps, exerting a controlled pulling force in multiple directions away from the gastric wall ([Fig. 1]) [2]. In this case, we completed a successful gastric angle ESD with the assistance of FASTER ([Video 1]). Firstly, a flat lesion was observed at the gastric angle ([Fig. 2]). Then, lesion marking, submucosal injection, and circumferential mucosal incision were performed. Next, the robot arm was attached to the tip of the conventional endoscope by a soft hood. The forceps were fixed at the six oʼclock position to grasp the lesion edge, providing downward traction. The operation progressed with an antegrade approach from the angle to the antrum. During the process, the submucosa was completely exposed and blood vessels were clearly visible ([Fig. 3], [Fig. 4]). The position of the forceps could also be changed to achieve multi-position traction. Finally, the lesion was successfully completely removed ([Fig. 5]). The total duration of the submucosal dissection was about 33 minutes. There were no complications during the operation. In our experience, we believe that FASTER has three representative advantages: (1) because of its flexibility, traction in both multi-position and multi-angle can be achieved; (2) it enabled an antegrade, tangential approach; and (3) it can effectively cope with difficult gastric angle lesions. It is not difficult to see that FASTER makes ESD easier and safer and provides a new strategy for gastric ESD. More cases and longer follow-up are needed to validate the advantage of this technique. Endoscopy_UCTN_Code_TTT_1AO_2AG Article published online: 17 January 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany